DFMTI (MK5435) is primarily used in pharmaceutical research and development, particularly in the study of metabolic disorders and diabetes. It functions as a potent and selective inhibitor of sodium-glucose co-transporter 2 (SGLT2), which plays a key role in glucose reabsorption in the kidneys. By inhibiting SGLT2, DFMTI helps reduce blood glucose levels, making it a promising candidate for the treatment of type 2 diabetes. Its application extends to preclinical studies where it is used to evaluate efficacy, safety, and mechanisms of action in animal models. Additionally, DFMTI contributes to the development of novel therapeutic strategies aimed at improving glucose control and managing associated complications in diabetic patients.